207 related articles for article (PubMed ID: 17228884)
1. Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains.
Zhou HB; Sheng S; Compton DR; Kim Y; Joachimiak A; Sharma S; Carlson KE; Katzenellenbogen BS; Nettles KW; Greene GL; Katzenellenbogen JA
J Med Chem; 2007 Jan; 50(2):399-403. PubMed ID: 17228884
[TBL] [Abstract][Full Text] [Related]
2. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity.
Compton DR; Sheng S; Carlson KE; Rebacz NA; Lee IY; Katzenellenbogen BS; Katzenellenbogen JA
J Med Chem; 2004 Nov; 47(24):5872-93. PubMed ID: 15537344
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor ligands. Part 5: The SAR of dihydrobenzoxathiins containing modified basic side chains.
Tan Q; Birzin ET; Chan W; Tien Yang Y; Pai LY; Hayes EC; DaSilva CA; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
Bioorg Med Chem Lett; 2004 Jul; 14(14):3747-51. PubMed ID: 15203155
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
5. Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alpha and beta.
Roelens F; Heldring N; Dhooge W; Bengtsson M; Comhaire F; Gustafsson JA; Treuter E; De Keukeleire D
J Med Chem; 2006 Dec; 49(25):7357-65. PubMed ID: 17149865
[TBL] [Abstract][Full Text] [Related]
6. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
8. New scaffolds for the design of selective estrogen receptor modulators.
Martín-Santamaría S; Rodríguez JJ; de Pascual-Teresa S; Gordon S; Bengtsson M; Garrido-Laguna I; Rubio-Viqueira B; López-Casas PP; Hidalgo M; de Pascual-Teresa B; Ramos A
Org Biomol Chem; 2008 Oct; 6(19):3486-96. PubMed ID: 19082149
[TBL] [Abstract][Full Text] [Related]
9. Pyrazolo[1,5-a]pyrimidines as estrogen receptor ligands: defining the orientation of a novel heterocyclic core.
Compton DR; Carlson KE; Katzenellenbogen JA
Bioorg Med Chem Lett; 2004 Nov; 14(22):5681-4. PubMed ID: 15482947
[TBL] [Abstract][Full Text] [Related]
10. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.
Berger DM; Torres N; Dutia M; Powell D; Ciszewski G; Gopalsamy A; Levin JI; Kim KH; Xu W; Wilhelm J; Hu Y; Collins K; Feldberg L; Kim S; Frommer E; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 Dec; 19(23):6519-23. PubMed ID: 19864136
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of estrogen receptor-beta selective ligands.
Manas ES; Unwalla RJ; Xu ZB; Malamas MS; Miller CP; Harris HA; Hsiao C; Akopian T; Hum WT; Malakian K; Wolfrom S; Bapat A; Bhat RA; Stahl ML; Somers WS; Alvarez JC
J Am Chem Soc; 2004 Nov; 126(46):15106-19. PubMed ID: 15548008
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones.
McDevitt RE; Malamas MS; Manas ES; Unwalla RJ; Xu ZB; Miller CP; Harris HA
Bioorg Med Chem Lett; 2005 Jun; 15(12):3137-42. PubMed ID: 15876535
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.
Shen J; Tan C; Zhang Y; Li X; Li W; Huang J; Shen X; Tang Y
J Med Chem; 2010 Jul; 53(14):5361-5. PubMed ID: 20553023
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding.
Rodriguez AL; Tamrazi A; Collins ML; Katzenellenbogen JA
J Med Chem; 2004 Jan; 47(3):600-11. PubMed ID: 14736241
[TBL] [Abstract][Full Text] [Related]
16. Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies.
Da Settimo F; Primofiore G; La Motta C; Taliani S; Simorini F; Marini AM; Mugnaini L; Lavecchia A; Novellino E; Tuscano D; Martini C
J Med Chem; 2005 Aug; 48(16):5162-74. PubMed ID: 16078836
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
[TBL] [Abstract][Full Text] [Related]
18. Novel 3,6,7-substituted pyrazolopyrimidines as positive allosteric modulators for the hydroxycarboxylic acid receptor 2 (GPR109A).
Blad CC; van Veldhoven JP; Klopman C; Wolfram DR; Brussee J; Lane JR; Ijzerman AP
J Med Chem; 2012 Apr; 55(7):3563-7. PubMed ID: 22420767
[TBL] [Abstract][Full Text] [Related]
19. ERbeta ligands. Part 2: Synthesis and structure-activity relationships of a series of 4-hydroxy-biphenyl-carbaldehyde oxime derivatives.
Yang C; Edsall R; Harris HA; Zhang X; Manas ES; Mewshaw RE
Bioorg Med Chem; 2004 May; 12(10):2553-70. PubMed ID: 15110838
[TBL] [Abstract][Full Text] [Related]
20. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
